Tiragolumab + Atezolizumab for Non-Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines a combination of drugs to treat locally advanced, untreated non-small cell lung cancer (NSCLC). It evaluates the safety and effectiveness of administering these drugs before surgery and continuing treatment afterward. The trial includes two groups: one for patients with high PD-L1 levels (a protein related to cancer growth) and another for all PD-L1 levels. Patients with stage II or III NSCLC who are eligible for surgery and have not received prior lung cancer treatment may be suitable candidates for this study. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of participants.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that the combination of tiragolumab and atezolizumab has been studied before. These studies primarily assessed the treatment's effectiveness and provided some safety information. For instance, patients generally tolerated the combination well, with common side effects such as tiredness and nausea, typical for cancer treatments.
While the treatment did not significantly improve survival rates, this does not imply it is unsafe. The progression to a Phase 2 trial indicates that earlier studies deemed it safe enough for broader testing. Phase 2 trials emphasize safety, so this trial will further confirm the treatment's safety profile.12345Why are researchers excited about this trial's treatments?
Researchers are excited about the combination of tiragolumab and atezolizumab for treating non-small cell lung cancer because it leverages a novel immune-boosting approach. While typical treatments often focus on standard chemotherapy and PD-1/PD-L1 inhibitors like pembrolizumab, this combination targets the TIGIT pathway alongside PD-L1, potentially offering a more robust immune response against cancer cells. This dual-action mechanism could enhance the body's ability to fight tumors more effectively than traditional therapies alone. Additionally, the flexibility to tailor post-surgery treatments based on patient-specific factors is a promising strategy for personalized cancer care.
What evidence suggests that this trial's treatments could be effective for non-small cell lung cancer?
Research has shown that using tiragolumab with atezolizumab hasn't consistently improved treatment outcomes for non-small cell lung cancer (NSCLC). Studies found that this combination did not extend patients' lives or delay cancer growth compared to atezolizumab alone, even in those with high levels of the protein PD-L1. In this trial, participants in Cohort A, with high PD-L1 expression, will receive neoadjuvant atezolizumab plus tiragolumab. Meanwhile, Cohort B, which includes participants with any PD-L1 expression level, will receive neoadjuvant atezolizumab plus tiragolumab along with chemotherapy. Despite previous results, researchers continue to explore different ways to use these drugs to determine if they might be beneficial in other situations.24678
Who Is on the Research Team?
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Are You a Good Fit for This Trial?
This trial is for adults with untreated Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) who can have platinum-based chemotherapy and surgery. They must be in good health otherwise, not HIV positive, and without a history of certain other cancers or severe infections.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Neoadjuvant Treatment
Participants receive neoadjuvant atezolizumab plus tiragolumab, with or without chemotherapy, for 4 cycles
Surgical Resection
Participants undergo surgical resection of the tumor
Adjuvant Treatment
Participants receive adjuvant atezolizumab plus tiragolumab for 16 cycles or adjuvant chemotherapy for 4 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Atezolizumab
- Carboplatin
- Cisplatin
- Tiragolumab
Atezolizumab is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University